Skip to main content
. 2015 Oct 19;6(40):42632–42650. doi: 10.18632/oncotarget.5822

Figure 8. Cell proliferation inhibition by combining sub-effective doses of ACSL4 and ER pathway inhibitors.

Figure 8

MCF-7 Tet-Off/ACSL4 cells were plated as described in Figure 7 and then incubated with rosiglitazone (10 or 25 μM) and/or 4-hidroxitamoxifen (4-OHTAM 2.5 or 5 μM) for 96 h. Subsequently, cell proliferation was measured by BrdU incorporation assays A.. Data are presented as inhibition of cell proliferation compared to control cells. White bars indicate a single inhibitor treatment while grey bars indicate combined inhibitor treatment. Data are presented as means ± SD. a, b, c, and d: ***p < 0.001 vs. corresponding single inhibitors; e: ***p < 0.001 vs. 4-OHTAM 2.5 μM + rosiglitazone 10 μM. MCF-7 Tet-Off/ACSL4 cells were incubated in the presence or absence of rosiglitazone (75 μM) alone or in combination with GW9662 (10 μM) for 24 h. ERα and mTOR-related protein levels were evaluated by Western blot and a representative blot is shown B..